Ernexa Therapeutics Inc.
ERNA
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.4M
$2.96
▼ -7.50%
P/E
—
Mkt Cap
$1.4M
52-Wk Range
$2.84–$71.50
52-Week Range
$2.84 - $71.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 90.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary iMSC technology platform enabling precise cytokine delivery to target tissues
- Dual therapeutic approach addressing both oncology and autoimmune indications
- Strategic partnership with Factor Bioscience Limited for enhanced development capabilities
- First-mover advantage in engineered iMSC-based immunotherapy space
Bear Case
1 risk
- High volatility (beta 2.6). Larger-than-normal price swings expected.
Growth
Stable outlook
Clinical advancement of ERNA-101 and ERNA-102 through development pipeline
Value
Valuation data unavailable
Momentum
Falling
-54.0% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying ERNA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 6, 2026
Reported EPS of -$3.40 vs -$3.30 consensus (-3.0% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-3.0%
Revenue trend · last 8Q
—
—
-100%
-100%
-100%
-100%
—
—
Q2 24
Q3 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$47.0K
$487.0K
$0
$0
$0
$0
$0
$0
Margins · last 8Q
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ERNA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related